Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53

Cancer Biology and Therapy

Volumn 12, Issue 12, 2011, Pages 1059-1068

  Warnock, Lorna Jane ^a   Raines, Sally Anne ^a   Milner, Jo ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Acetylation; Aurora A; Cross talk; p53; Phosphorylation

Indexed keywords

AURORA A KINASE; PROTEIN P53;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; COLON CARCINOMA; CONTROLLED STUDY; DRUG TARGETING; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; EPITOPES; HCT116 CELLS; HUMANS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84055190755     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.12.18141     Document Type: Article

References (61)

1. Lukashchuk N, Vousden KH. Ubiquitination and degradation of mutant p53. Mol Cell Biol 2007; 27:8284-95; PMID:17908790; http://dx.doi.org/10. 1128/MCB.00050-07
2. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8:275-83; PMID:17380161; http://dx.doi.org/10.1038/nrm2147
3. Vousden KH. Outcome of p53 activation - spoilt for choice. J Cell Sci 2006; 119:5015-20; PMID:17158908; http://dx.doi.org/10.1242/jcs.03293
4. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, et al. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 2000; 14:981-93; PMID:10783169
5. Dai C, Gu W. p53 post-translational modification: deregulation in tumorigenesis. Trends Mol Med 2010; 16:528-36; PMID:20932800; http://dx.doi.org/10. 1016/j.molmed.2010.09.002
6. Barlev NA, Liu L, Chehab NH, Mansfield K, Halazonteis TD, Berger SL. Acetylation of p53 activates transcription through recruitment of coactivators/ histone acetyltransferases. Mol Cell 2001; 8:1243-54; PMID:11779500; http://dx.doi.org/10.1016/S1097- 2765(01)00414-2
7. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: The molecular basis for p53 regulation. Curr Opin Cell Biol 2003; 15:164-71; PMID:12648672; http://dx.doi.org/10.1016/S0955-0674(03)00003-6
8. Carter S, Vousden KH. Modifications of p53: competing for the lysines. Curr Opin Genet Dev 2009; 19:18-24; PMID:19179064; http://dx.doi.org/10.1016/j. gde.2008. 11.010
9. Hamroun D, Kato S, Ishioka C, Claustres M, Beroud C, Soussi T. TheUMD TP53 database and website: Update and revisions. Hum Mutat 2006; 27:14-20; PMID: 16278824; http://dx.doi.org/10.1002/humu.20269
10. Lentini L, Amato A, Schillaci T, Di Leonardo A. Simultaneous Aurora-A/STK15 overexpression and centrosome amplification induce chromosomal instability in tumour cells with a MIN phenotype. BMC Cancer 2007; 7:212-20; PMID:17999753; http://dx. doi.org/10.1186/1471-2407-7-212
11. Karthigeyan D, Prasad SBB, Shandilya J, Agrawal S, Kundu TK. Biology of Aurora A kinase: Implications of cancer manifestation and therapy. Med Res Rev 2010; PMID:20196102; http://dx.doi.org/10.1002/ med.20203
12. Li C-C, Chu H-Y, Yang C-W, Chou C-K, Tsai T-F. Aurora-A overexpression in mouse liver causes p53- dependent premitotic arrest during liver regeneration. Mol Cancer Res 2009; 7:678-88; PMID:19435814; http://dx.doi.org/10.1158/1541- 7786.MCR-08-0483
13. Mao J-H, Wu D, Perez-Losada J, Jiang T, Li Q, Neve RM, et al. Crosstalk between Aurora-A and p53: Frequent deletion or downregulation of Aurora-A in tumours from p53 null mice. Cancer Cell 2007; 11:161-73; PMID:17292827; http://dx.doi.org/10. 1016/j.ccr.2006.11.025
14. Marumoto T, Zhang D, Saya H. Aurora-A - Guardian of the poles. Nat Rev Cancer 2005; 5:42-50; PMID: 15630414; http://dx.doi.org/10.1038/nrc1526
15. Gautschi O, Heighway J, Mack PC, Pumell PR, Lara PN, Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008; 14:1639-48; PMID:18347165; http://dx.doi.org/10.1158/1078-0432.CCR-07-2179
16. Chen SS, Chang PC, Cheng YW, Tang FM, Lin YS. Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function. EMBO J 2002; 21:4491-9; PMID:12198151; http://dx.doi.org/ 10.1093/emboj/cdf409
17. Liu Q, Kaneko S, Yang L, Feldman RI, Nicosia SV, Chen J, et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 2004; 279:52175-82; PMID: 15469940; http://dx.doi.org/10.1074/jbc.M406802200
18. Fujii Y, Yada M, Nishiyama M, Kamura T, Takahashi H, Tsunematsur R. Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitindependent degradation. Cancer Sci 2006; 97:729-36; PMID:16863506; http://dx.doi.org/10.1111/j.1349- 7006.2006.00239.x
19. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutants in p53 produce common conformational defects. A monoclonal antibody specific for the mutant p53 form. EMBO J 1990; 9:1595-602.
20. Wang PL, Sait F, Winter G. The 'wild type' conformation of p53: Epitope mapping using hybrid proteins. Oncogene 2001; 20:2318-24; PMID:11402327; http://dx.doi.org/10.1038/sj.onc.1204316
21. Stephen CW, Helminen P, Lane DP. Characteristics of epitopes on human p53 using phage-displayed peptide libraries: Insights into antibody-peptide interactions. J Mol Biol 1995; 248:58-78; PMID:7537340; http://dx. doi.org/10.1006/jmbi.1995.0202
22. Dey A, Verma CS, Lane DP. Updates on p53: modulation of p53 degradation as a therapeutic approach. Br J Cancer 2008; 98:4-8; PMID:18182973; http://dx.doi. org/10.1038/sj.bjc.6604098
23. Warnock LJ, Raines SA, Mee TR, Milner J. Role of phosphorylation in p53 acetylation and PAb421 epitope recognition in baculoviral and mammalian expressed proteins. FEBS J 2005; 272:1669-75; PMID:15794754; http://dx.doi.org/10.1111/j.1742-4658.2005.04589.x
24. Warnock LJ, Adamson R, Lynch CJ, Milner J. Crosstalk between site-specific modifications on p53 and histone H3. Oncogene 2008; 27:1639-44; PMID:17891183; http://dx.doi.org/10.1038/sj.onc.1210787
25. Warnock LJ, Knox A, Mee TR, Raines SA, Milner J. Influence of tetramerisation on site-specific posttranslational modifications of p53: comparison of human and murine p53 tumour suppressor protein. Cancer Biol Ther 2008; 7:1481-9; http://dx.doi.org/ 10.4161/cbt.7.9.6473
26. Royds JA, Iacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ 2006; 13:1017- 26; PMID:16557268; http://dx.doi.org/10.1038/ sj. cdd.4401913
27. Bourdon J-C, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas D, et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005; 19: 2122-37; PMID:16131611; http://dx.doi.org/10.1101/ gad.1339905
28. Vojtesek B, Dolezalove H, Lauerova L, Svitakova M, Havlis P, Kovarik J, et al. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene 1995; 10:389-93; PMID:7530828
29. Warnock LJ, Raines SA, Milner J. Restoration of wild-type conformation to full-length and truncated p53 proteins. Cancer Biol Ther 2004; 3:634-7; PMID: 15136763; http://dx.doi.org/10.4161/cbt.3.7.915
30. Lane D. p53 from pathway to therapy. Carcinogenesis 2004; 25:1077-81; PMID:15205365; http://dx.doi. org/10.1093/carcin/bgh186
31. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E, et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999; 18:6845-54; PMID:10581258; http:// dx.doi.org/10.1093/emboj/18.23.6845
32. Meek DW, Anderson CW. Posttranslational modification of p53: Cooperative integrators of function. Cold Spring Harb Perspect Biol 2009; 1:a000950- 16; PMID:20457558; http://dx.doi.org/10.1101/ cshperspect.a000950
33. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell 2008; 133:612- 26; PMID:18485870; http://dx.doi.org/10. 1016/j.cell. 2008.03.025
34. Mellert H, Sykes SM, Murphy ME, McMahon SB. The ARF/Oncogene pathway activates p53 acetylation within the DNA binding domain. Cell Cycle 2007; 6:1304-6; PMID:17534149; http://dx.doi.org/10. 4161/cc.6.11.4343
35. Joubel A, Chalkley RJ, Medzihradszky KF, Hondermarck H, Burlingame AL. Identification of new p53 acetylation sites in COS-1 cells. Mol Cell Proteomics 2009; 8:1167-73; PMID:19155208; http:// dx.doi.org/10.1074/mcp.M800487-MCP200
36. Sakaguchi K, Sakamoto H, Lewis MS, Anderson CW, Erikson JW, Appella E, et al. Phosphorylation of serine 392 stabilizes the tetramer formation of tumour suppressor protein p53. Biochemistry 1997; 36:10117-24; PMID:9254608; http://dx.doi.org/10.1021/bi970759w
37. Ashcroft M, Kubbutat MH, Vousden KH. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 1999; 19:1751-8; PMID:10022862
38. Saito S, Yamagichi H, Higashimoto Y, Chao C, Xu Y, Fornace AJ, Jr., et al. Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem 2003; 278:37536- 44; PMID:12860987; http://dx.doi.org/10.1074/jbc. M305135200
39. Maya R, Oren M. Unmasking of phosphorylation-sensitive epitopes on p53 and mdm2 by a simple Western-phosphatase procedure. Oncogene 2000; 19:3213-5; PMID:10918576; http://dx.doi.org/10. 1038/sj.onc.1203658
40. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 2006; 24:841-51; PMID:17189187; http://dx.doi.org/10.1016/j.molcel.2006.11. 026
41. Neve RM, Chin K, Fridlyand J, Yeh H, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for study of functionally distinct cancer subtypes. Cancer Cell 2006; 10:515-27; PMID:17157791; http://dx.doi. org/10.1016/j.ccr.2006.10.008
42. Ito A, Lai C-H, Saito S, Hamilton MH, Appella E, Tao T-P. p300/CBP-mediated acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 2001; 20:1331-40; PMID: 11250899; http://dx.doi.org/ 10.1093/emboj/20.6.1331
43. Jenkins LM, Yamaguchui H, Hayashi R, Cherry S, Tropea JE, Miller M, et al. Two distinct motifs within the p53 transactivation domain bind to the Tad2 domain of p300 and are differently affected by phosphorylation. Biochemistry 2009; 48:1244- 55; PMID:19166313; http://dx.doi.org/10.1021/ bi801716h
44. Matsumoto M, Furihata M, Ohtsuki Y. Posttranslational phosphorylation of mutant p53 protein in tumor development. Med Mol Morphol 2006; 39:79-87; PMID:16821145; http://dx.doi.org/10. 1007/s00795-006-0320-0
45. Scrittori L, Hans F, Anglevo D, Charra M, Prigent C. pEG2 Aurora-A kinase, Histone H3 phosphorylation and chromosome assembly in Xenopus egg extract. J Biol Chem 2001; 276:30002-10; PMID:11402032; http://dx.doi.org/10. 1074/jbc.M102701200
46. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293:1074-80; PMID:11498575; http:// dx.doi.org/10.1126/science.1063127
47. Allison SJ, Milner J. Loss of p53 has site-specific effects on Histone H3 modification, including serine 10 phosphorylation importance for maintenance of ploidy. Cancer Res 2003; 63:6674-9; PMID:14583461
48. Rubbi CP, Milner J. p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage. EMBO J 2003; 22:975-86; PMID:12574133; http:// dx.doi.org/10.1093/emboj/cdg082
49. Espinosa JM, Emerson BM. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 2001; 8:57-69; PMID:11511360; http://dx.doi.org/10.1016/ S1097-2765(01)00283-0
50. Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001; 268:2764-72; PMID:11358490; http://dx.doi.org/10.1046/j.1432-1327.2001.02225.x
51. Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell 2007; 25:725-38; PMID: 17349958; http://dx.doi.org/10. 1016/j.molcel.2007. 02.007
52. Olsson A, Manzl C, Strasser A, Villunger A. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ 2007; 14:1561-75; PMID:17627286; http://dx.doi.org/10.1038/sj.cdd. 4402196
53. Wulf GM, Liou YC, Ryo A, Lee SW, Lu KP. Role of Pin 1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem 2002; 277:47976-9; http://dx.doi.org/10.1074/jbc. C200538200
54. Okorokov AL, Sherman MB, Plisson C, Grinkevich V, Sigmundsson K, Selivanova G, et al. The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity. EMBO J 2006; 25:5191-200; PMID:17053786; http://dx.doi.org/10.1038/sj.emboj. 7601382
55. Kojima K, Konopleva M, Nakakuma H, Andreeff M. Concomitant inhibition of Mdm2-p53 interaction and Aurora-A kinases activates the p53-dependent post-mitotic checkpoints and synergistically induces p53- mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood 2008; 112:2886-95; PMID:18633130; http:// dx.doi.org/10.1182/blood-2008- 01-128611
56. Hoar K, Chakravarty A, Rabino C, Wysong D, Bowman D, Ray N, et al. MLN8054, a small-molecule inhibitor of Aurora A causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 2007; 27:4513-25; PMID:17438137; http://dx.doi.org/10.1128/MCB.02364-06
57. Scarpini S, Roupret M, Renard-Penna R, Camparo P, Cussenot O, Comperat E. Impact of the expression of Aurora-A, p53 and Mib-1 on the prognosis of urothelial carcinomas of the upper urinary tract. Urol Oncol 2010; [Epub ahead of print].
58. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, et al. Disruption of human p53 in cancer cells alters the response to therapeutic agents. J Clin Invest 1999; 104:263-9; PMID:10430607; http://dx.doi.org/ 10.1172/JCI6863
59. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 1996; 62:155-69; PMID:8698076; http://dx.doi.org/10. 1006/exer.1996.0020
60. Wang XX, Liu R, Jin SQ, Fan FY, Zhan QM. Overexpression of Aurora-A kinase promotes tumour cell proliferation and inhibits apoptosis in esophageal squamous cell carcinoma cell line. Cell Res 2006; 16:356-66; PMID:16617331; http://dx.doi.org/10. 1038/sj.cr.7310046
61. Allison SJ, Jiang M, Milner J. Oncogenic viral protein HPV E7 up-regulates the SIRT1 longevity protein in human cervical cancer cells. Aging (Albany NY) 2009; 1:316-27; PMID:20157519